11 funding opportunities found in this category. Change the order of results: Newest First Oldest First Expiring Soonest Expiring Latest Lowest Award to Highest Highest Award to Lowest
Siemens Healthcare Diagnostics Young Investigator Award
Honors outstanding laboratory research in clinical microbiology or antimicrobial agents and is intended to further the career development of a young clinical scientist and promote awareness of clinical microbiology as a career. Eligibility: The nominee should be conducting outstanding research in clinical microbiology, automation in clinical laboratories, development of novel antimicrobial agents, mechanisms of action of antimicrobial agents or mechanisms of resistance to antimicrobial agents. The nominee must be no more than five years beyond completion of postdoctoral research training in microbiology, infectious diseases or related disciplines at the time of the nomination deadline. Award: A cash prize of $2,500, commemorative piece, and travel to the ASM General Meeting.
Deadline: July 1.
Nominations: Nominations will be considered for three years as long as the nominee continues to meet the eligibility criteria and an updated curriculum vitae is submitted annually. Self-nominations and more than one nomination per nominee will not be accepted. Only one nominating form and two supporting forms are accepted per nomination. The two supporters must be persons other than the nominator who are familiar with the nominee's qualifications and accomplishments. Only one of the three individuals involved in the nomination may be employed at the nominee's institution. The nominator and supporters must not share employers.
Nominations must consist of the following:
Curriculum vitae, including a list of publications, abstracts, and manuscripts in preparation, emailed to awards@asmusa.org Nominating form Supporting form
ASM awards are granted at the discretion of award selection committees and may not be awarded every year.
Sponsor: Siemens Healthcare Diagnostics
American Society for Microbiology 1752 N Street, N.W. Washington, D.C. 20036-2904 (202) 737-3600
Autism Speaks Request for Applications: Treatment Research Grants: Full- and Pilot-Level 2012 Cycle
Letter of Intent due: February 23, 2012, 8:00 PM Eastern Autism Speaks invites both Full- and Pilot-Level Treatment research grant applications to conduct innovative clinical studies of novel interventions for individuals with Autism Spectrum Disorders (ASD) throughout the lifespan. These may include medical approaches including complementary and alternative forms of health care and pharmacological treatments, as well as behavioral and/or psychosocial interventions, and evaluation of the efficacy, safety or therapeutic benefits of all types of interventions. Also appropriate are animal model studies that test the effects of novel compounds for reducing autism symptoms.
For all RFAs, Autism Speaks is focusing on a set of targeted research priorities for 2012. All treatment study projects will be required to demonstrate direct relevance to at least one of these targeted research priorities:
1. Understand environmental risk factors and their interaction with genetic susceptibility to enable prevention and improve diagnosis and treatment
2. Discover biomarkers that can improve risk assessment and subtype stratification that will allow for an individualized approach to treatment
3. Improve quality of life through more effective medicines, behavioral interventions, and technologies
4. Enhance diagnosis and treatment of underserved and under-studied populations, specifically,
• Nonverbal persons with ASD • Ethnically-diverse and/or low resource communities • Adults • Those with medical co-morbidities
5. Disseminate and implement evidence-based clinical practices to the broader community worldwide IMPORTANT: The relevance of the proposed research to ASD and Autism Speaks’ research priority areas must be explicitly described in the Letter of Intent (LOI) and full application.
Awards Autism Speaks will make a limited number of treatment research grants determined by the available financial resources. Full-level research grant 1-3 years $150,000/year maximum
Pilot-level research grant 1-2 years $60,000/year maximum
Autism Speaks utilizes a web-based application system for their grant submissions. All applications must be submitted through this system. It is imperative to indicate whether the submission is for the Full- or Pilot-Level Treatment research option.
Research Inquiries research@autismspeaks.org
Epilepsy Therapy Project/Epilepsy Foundation New Therapy - Commercialization Grants Program
Letter of Intent due: March 1, 2012, 11:59 PM ET
If LOI is accepted, APPLICATION is due: April 12, 2012, 11:59 PM ET
The New Therapy - Commercialization Grants Program is a unique partnership between two leading epilepsy non-profit organizations, the Epilepsy Therapy Project and the Epilepsy Foundation. The mission of the New Therapy - Commercialization Grants Program is to drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. Funding is provided to academic and commercial groups worldwide. The Program seeks to advance the development of new therapies including but not limited to medicines, biologics or devices. All proposals must demonstrate a clear path from the lab to the patient and are evaluated with consideration for their potential value to patients, likelihood of successful development including regulatory approval and the timeframe of development. The Program also encourages 1:1 matching grants to academic and commercial entities to support the commercialization of novel approaches to the treatment of epilepsy. Preference will be given to proposals that already have a commercial partner engaged to assist with development, and to proposals that have committed or matched funding from a sponsoring institution, commercial partner or other third party source.
Applicants must demonstrate background work beyond the basic science discovery stage.
Areas of interest include:
Novel approaches to treatment. Platform technology to advance screening techniques that can be utilized by multiple laboratories, including utility of techniques for early proof-of-concept trials. Adaptation of treatment in development for another therapeutic area to assess utility for epilepsy (while maintaining patent protection).
All proposals will be evaluated by our Business and Scientific Advisory Boards, as described below:
Proposals are rated on the likelihood of success by the Business Advisory Board as:
Intellectual Property Strategy & Status; Freedom To Operate Can this Get to Patients: Investment Potential & Likelihood of Ongoing Funding Support Probability of Success / Time Factor Fit with Program Mission / Patient Impact Overall Impression
Proposals are rated on the likelihood of success by the Scientific Advisory Board as:
Quality of Science Probability of Successful completion of milestones / outlined program Timeframe of Success Fit with Program Mission / Impact on Patients Overall Impression
These grants are awarded only to programs that have progressed beyond the basic science discovery stage. Investigators are strongly advised to have their compounds screened, as appropriate, by the NINDS ASP Program, http://www.ninds.nih.gov/research/asp/index.htm. Investigators are expected to have an established record of achievement in the area. Full intellectual property (IP) rights (composition of matter) are preferred over method of use IP. Clinical programs must have a reasonable protocol and sample size to assure that the results will be meaningful; studies of patients should describe the type of seizure/epilepsy that will be investigated. Device programs should present novel concepts for treatment.
Confidential information should NOT be sent to ETP or provided in any grant application without advance discussion with ETP and only with appropriate confidentiality agreements.
Scientific questions about appropriateness of an application should be directed to Roger J. Porter, MD, roger@epilepsytherapyproject.org.
Investigators must submit a Letter of Intent by March 1, 2012 by 11:59 pm ET.
The deadline for receipt of full Grant proposals is April 12, 2012 by 11:59 pm ET.
Full proposals will be accepted only from Investigators whose Letter of Intent was approved.
Epilepsy Foundation Targeted Research Initiative for Youth
Application Deadline: March 21, 2012
Award Amount: up to $50,000 maximum for one year
Apply via Proposal Central website
The Targeted Research Initiative for Youth grant program recognizes the increasing need for epilepsy and seizure research in populations from birth through the teen years involving pathophysiology, epidemiology, diagnosis, behavioral manifestations, medication therapy, and quality-of-life issues.
The Foundation invites research grant applications from investigators interested in psychosocial problems and comorbidities of infants, children and adolescents with epilepsy including, but not limited to topics such as psychiatric comorbidity; treatment of behavioral and cognitive comorbidities, including innovative techniques such as utilization of internet or computer based technologies; studies of the impact of impaired social cognition on educational and occupational outcomes; difficulties and treatment gaps for adolescents transitioning to adulthood; social supports for adolescents with epilepsy; health access and literacy including family communication with health care professionals; the impact of other health conditions (e.g. sleep difficulties, migraines, etc.) on epilepsy treatment and outcome.
Applicants may request up to $50,000 maximum for one year.
Epilepsy Foundation 8301 Professional Place Landover, MD 20785-7223 Telephone: 1-800-332-1000 Fax: 1-301-577-2684 Email: ContactUs@efa.org
Focused Ultrasound Surgery Foundation Research Awards
Full proposals are accepted on a rolling basis but MUST be received on or before the quarterly submission deadline* if they are to be considered for the next funding cycle.
*Submission Deadlines: July 1, October 1, January 3, April 1
Successful applicants will normally be funded up to $100,000 for one year. Larger projects and longer funding periods may be considered for exceptional proposals. Awards are made contingent upon the availability of funds.
Award funds may only be used to support the direct costs of research. Award funds MAY NOT be used to cover institutional overhead or indirect costs. Allowable costs include salary for the principal investigator and for scientific and/or clinical research personnel directly involved in the research project, consumable supplies and animals, costs associated with data collection and analysis, IRB review fees and travel related to the conduct of the research or for the purpose of presenting the results of the research at scientific or medical meetings.
It is considered advantageous if institutional/departmental support and/or support from other sources—such as the NIH, foundations, or other philanthropic organizations—is available for the research project for which Focused Ultrasound Surgery Foundation funding is requested.
Focused Ultrasound Surgery Foundation 1230 Cedars Court, Suite F Charlottesville, VA 22903
434.220.4993
American Orthopaedic Society for Sports Medicine/Smith & Nephew Innovative Outcomes Assessment Grant
AOSSM is pleased to announce a new grant sponsored by Smith & Nephew to support development of innovative approaches to measuring the effects of surgical procedures in orthopaedic sports medicine. This $25,000 grant is meant to advance the evaluation of clinical outcomes related to surgery by encouraging development of novel approaches, techniques, and/or methodology that will facilitate and enhance clinical research. Examples might include new web-based instruments to allow inter-institutional collaborative efforts, tools to quantify joint laxity, or innovative methods to measure the results of arthroscopic procedures about the hip. The intent of this award is to provide start-up funding for the development of tools and/or technology that can be leveraged and used for future, larger-scale clinical research studies.
Applications for this grant will be judged on three criteria:
• Innovation • Feasibility • Clinical Significance
The proposal should define the limitations with currently available assessments, clearly describe the proposed innovative approach, state how the new assessment will be tested, and discuss the clinical significance of this novel method to the field if successful. Because this grant is intended to foster new ideas and creativity, prior data related to the innovation is not required but can be presented to establish feasibility. Deadline for applications is April 17, 2012. The principal investigator or a co-investigator must be an AOSSM member in good standing.
All information should be submitted in one pdf document to Bart Mann, AOSSM Director of Research.
AOSSM gratefully acknowledges Smith & Nephew for the educational grant to support this activity.
American Orthopaedic Society for Sports Medicine 6300 N River Road Suite 500 Rosemont, IL 60018 847/292-4900 847/292-4905 fax 877/321-3500
Shwachman Diamond Syndrome Foundation Research Grants
Shwachman-Diamond Syndrome (SDS) is a multi-system autosomal-recessive disorder characterized by exocrine pancreatic dysfunction, and varying degrees of marrow dysfunction with cytopenias. Many associated clinical problems have also been described, including skeletal anomalies, metaphyseal dysostosis, rib abnormalities, cleft palate, dental abnormalities and others. Shwachman-Diamond Syndrome Foundation (SDSF) is a nonprofit support organization actively helping the victims of this disease. SDSF is accepting grant requests for research relevant to this disease. Any high quality, innovative research proposal deemed relevant to SDS will be considered.
The following are areas of particular interest: Investigate or evaluate potential novel therapies or potential novel therapeutic strategies- preferred applications Evaluate predictors of bone marrow abnormalities to determine their correlation with the disease Determine the causes of bone marrow failure and leukemia Further delineate the pathogenesis of pancreatic disease Investigations related to adult patient presentation, management, and care including transition from pediatric-centered to adult care Eligibility Persons applying for these grants must be in a faculty position with authority to hold an independent research grant (not a training position). Letter of Intent The potential applicant should write a one-page letter of intent to the SDSF, indicating the applicant’s position and affiliation, describing their planned project, and explaining its relevance to Shwachman-Diamond Syndrome. These letters are reviewed by SDSF’s Medical and Scientific Advisory Board (MSAB) grant review process. Purpose This letter will be used to identify applicants who will be asked to provide a full application. Dates The letter is due no later than March 12th. All those who have submitted a letter of intent will receive a reply by April 5th. All Grant Applications must be submitted by May 15th. The final grant decision will be announced by July 31st with a November 1st start date. Terms of Support Support may be provided for up to two (2) years in an amount not to exceed $65,000 per year, including expenses. The second year funding will not be released until a Progress Report has been reviewed and approved by the MSAB. The date for the Progress Report is October 1st. Applicants may submit only one grant application at a time, and may hold only one grant at a time. If you would like us to send you a grant application, have any questions regarding the grant process or have an interest in the disease, please contact SDSF. Please call toll free 1-888-825-SDSF (7373) or via email at info@shwachman-diamond.org.
Shwachman-Diamond Syndrome Foundation 127 Western Avenue Sherborn, MA 01770
Call for Applications: National Spasmodic Dysphonia Association Research Grant Program
The National Spasmodic Dysphonia Association is seeking research applications for new investigator startup grants or post doctoral study focused on research aimed at increasing understanding of spasmodic dysphonia.
Small seed money grants to new or established investigators for up to $20,000 (excluding indirect costs) per year will be awarded. These can be for startup grants enabling successful applicants to subsequently seek funding from the National Institutes of Health or may provide partial support for post doctoral research training relating to spasmodic dysphonia.
We are interested in hypothesis-driven research related to new approaches aimed at increasing understanding of Spasmodic Dysphonia that focuses on the following areas:
Endogenous and environmental risk factors for the development of Spasmodic Dysphonia Pathophysiology of central nervous system dysfunction in Spasmodic Dysphonia Animal models for Spasmodic Dysphonia Novel approaches to the treatment of Spasmodic Dysphonia Diagnostic tools for Spasmodic Dysphonia Controlled studies of treatment outcomes in Spasmodic Dysphonia
The deadline to submit an application is March 1 each year.
National Spasmodic Dysphonia Association 300 Park Boulevard Suite 415 Itasca, IL 60143 Phone: 800-795-6732 Fax: 630-250-4505 NSDA@dysphonia.org
12next
